image
Healthcare - Biotechnology - NASDAQ - CH
$ 44.25
-0.405 %
$ 3.82 B
Market Cap
-9.86
P/E
1. INTRINSIC VALUE

This DCF valuation model was last updated on Jun, 21, 2025.

The intrinsic value of one CRSP stock under the worst case scenario is HIDDEN Compared to the current market price of 44.2 USD, CRISPR Therapeutics AG is HIDDEN

This DCF valuation model was last updated on Jun, 21, 2025.

The intrinsic value of one CRSP stock under the base case scenario is HIDDEN Compared to the current market price of 44.2 USD, CRISPR Therapeutics AG is HIDDEN

This DCF valuation model was last updated on Jun, 21, 2025.

The intrinsic value of one CRSP stock under the best case scenario is HIDDEN Compared to the current market price of 44.2 USD, CRISPR Therapeutics AG is HIDDEN

2. FUNDAMENTAL ANALYSIS

Price Chart CRSP

image
$55.0$55.0$50.0$50.0$45.0$45.0$40.0$40.0$35.0$35.0$30.0$30.0Jan '25Jan '2515 Jan15 JanFeb '25Feb '2515 Feb15 FebMar '25Mar '2515 Mar15 MarApr '25Apr '2515 Apr15 AprMay '25May '2515 May15 MayJun '25Jun '2515 Jun15 Jun
FINANCIALS
35 M REVENUE
-90.57%
-467 M OPERATING INCOME
-109.66%
-366 M NET INCOME
-138.43%
-143 M OPERATING CASH FLOW
45.17%
-280 M INVESTING CASH FLOW
-74.87%
332 M FINANCING CASH FLOW
429.78%
865 K REVENUE
-97.53%
-148 M OPERATING INCOME
-129.80%
-136 M NET INCOME
-264.49%
-53.9 M OPERATING CASH FLOW
-7.83%
-19.8 M INVESTING CASH FLOW
-18.67%
10.6 M FINANCING CASH FLOW
-37.26%
Balance Sheet CRISPR Therapeutics AG
image
Current Assets 1.94 B
Cash & Short-Term Investments 1.9 B
Receivables 25 M
Other Current Assets 8.31 M
Non-Current Assets 305 M
Long-Term Investments 0
PP&E 278 M
Other Non-Current Assets 27.3 M
84.92 %12.38 %Total Assets$2.2b
Current Liabilities 87.8 M
Accounts Payable 14.7 M
Short-Term Debt 17.3 M
Other Current Liabilities 55.8 M
Non-Current Liabilities 222 M
Long-Term Debt 206 M
Other Non-Current Liabilities 15.8 M
4.75 %5.58 %18.00 %66.59 %5.09 %Total Liabilities$310.0m
EFFICIENCY
Earnings Waterfall CRISPR Therapeutics AG
image
Revenue 35 M
Cost Of Revenue 110 M
Gross Profit -75.2 M
Operating Expenses 504 M
Operating Income -467 M
Other Expenses -100 M
Net Income -366 M
100m100m00(100m)(100m)(200m)(200m)(300m)(300m)(400m)(400m)(500m)(500m)(600m)(600m)35m(110m)(75m)(504m)(467m)100m(366m)RevenueRevenueCost Of RevenueCost Of RevenueGross ProfitGross ProfitOperating ExpensesOperating ExpensesOperating IncomeOperating IncomeOther ExpensesOther ExpensesNet IncomeNet Income
RATIOS
-215.00% GROSS MARGIN
-215.00%
-1333.05% OPERATING MARGIN
-1333.05%
-1046.43% NET MARGIN
-1046.43%
-18.96% ROE
-18.96%
-16.34% ROA
-16.34%
-21.70% ROIC
-21.70%
FREE CASH FLOW ANALYSIS
Free Cash Flow Analysis CRISPR Therapeutics AG
image
500m500m400m400m300m300m200m200m100m100m00(100m)(100m)(200m)(200m)(300m)(300m)(400m)(400m)(500m)(500m)(600m)(600m)20162016201720172018201820192019202020202021202120222022202320232024202420252025
Net Income -366 M
Depreciation & Amortization 19.3 M
Capital Expenditures -1.9 M
Stock-Based Compensation 86.6 M
Change in Working Capital 156 M
Others -57.3 M
Free Cash Flow -145 M
3. WALL STREET ANALYSTS ESTIMATES
Wall Street Analysts Price Targets CRISPR Therapeutics AG
image
Wall Street analysts predict an average 1-year price target for CRSP of $75.7 , with forecasts ranging from a low of $59 to a high of $100 .
CRSP Lowest Price Target Wall Street Target
59 USD 33.33%
CRSP Average Price Target Wall Street Target
75.7 USD 71.11%
CRSP Highest Price Target Wall Street Target
100 USD 125.99%
Price
Max Price Target
Min Price Target
Average Price Target
1001009090808070706060505040403030Aug '24Aug '24Oct '24Oct '24Nov '24Nov '2420252025Feb '25Feb '25Apr '25Apr '25Jun '25Jun '25Jul '25Jul '25Aug '25Aug '25Oct '25Oct '25Nov '25Nov '2520262026Feb '26Feb '26Apr '26Apr '26Jun '26Jun '26
4. DIVIDEND ANALYSIS
5. COMPETITION
slide 2 of 11
6. Ownership
Insider Ownership CRISPR Therapeutics AG
image
Sold
0-3 MONTHS
141 K USD 1
3-6 MONTHS
4.37 M USD 4
6-9 MONTHS
2.74 M USD 2
9-12 MONTHS
189 K USD 1
Bought
0 USD 0
0-3 MONTHS
314 K USD 1
3-6 MONTHS
0 USD 0
6-9 MONTHS
0 USD 0
9-12 MONTHS
7. News
Can Casgevy Deliver a Turnaround for CRISPR Therapeutics? CRSP bets on Casgevy to drive growth, but its extremely high price tag and slow rollout test investor patience in a crowded field. zacks.com - 3 days ago
CRISPR Therapeutics AG (CRSP) Increases Despite Market Slip: Here's What You Need to Know The latest trading day saw CRISPR Therapeutics AG (CRSP) settling at $44.43, representing a +2.87% change from its previous close. zacks.com - 4 days ago
CRISPR Therapeutics AG (CRSP) Is a Trending Stock: Facts to Know Before Betting on It Zacks.com users have recently been watching CRISPR Therapeutics (CRSP) quite a bit. Thus, it is worth knowing the facts that could determine the stock's prospects. zacks.com - 4 days ago
Can a $10,000 Investment in CRISPR Therapeutics Turn Into $1 Million? CRSP's innovative pipeline shines, but the biotech does face regulatory risks and fierce competition. 247wallst.com - 1 week ago
Crispr Therapeutics: Betting On A One-Shot Future Crispr Therapeutics AG is transitioning to a commercial company, with CASGEVY's rollout and a robust pipeline in cardiovascular, autoimmune, and oncology driving long-term potential. The cardiovascular franchise, especially CTX-310 and CTX-320, offers blockbuster potential with best-in-class efficacy and a compelling one-time treatment value proposition. Recent partnerships, like Sirius Therapeutics, expand Crispr's multi-modal platform and open new multi-billion dollar market opportunities in siRNA and beyond. seekingalpha.com - 1 week ago
Biotech Stock for Options Bears to Target Right Now Biotech stock Crispr Therapeutics Inc's (NASDAQ:CRSP) June rally appears to be coming to an end. schaeffersresearch.com - 1 week ago
CRISPR Therapeutics Gains 14% in a Month: How to Play the Stock? CRSP surges 14% on encouraging CTX310 data and growing Casgevy sales, despite early-stage pipeline risks. zacks.com - 1 week ago
CRISPR Therapeutics AG (CRSP) Rises Higher Than Market: Key Facts The latest trading day saw CRISPR Therapeutics AG (CRSP) settling at $42.94, representing a +2.02% change from its previous close. zacks.com - 1 week ago
CRISPR Therapeutics AG (CRSP) Goldman Sachs 46th Annual Global Healthcare Conference (Transcript) CRISPR Therapeutics AG (NASDAQ:CRSP ) Goldman Sachs 46th Annual Global Healthcare Conference June 9, 2025 3:20 PM ET Company Participants Samarth Kulkarni - CEO & Chairman Conference Call Participants Salveen Jaswal Richter - Goldman Sachs Group, Inc., Research Division Salveen Jaswal Richter Good afternoon. Thank you, everyone, for joining us. seekingalpha.com - 1 week ago
Investors Heavily Search CRISPR Therapeutics AG (CRSP): Here is What You Need to Know CRISPR Therapeutics (CRSP) has been one of the stocks most watched by Zacks.com users lately. So, it is worth exploring what lies ahead for the stock. zacks.com - 2 weeks ago
CRISPR Therapeutics (CRSP) Up 11.1% Since Last Earnings Report: Can It Continue? CRISPR Therapeutics (CRSP) reported earnings 30 days ago. What's next for the stock? zacks.com - 2 weeks ago
Can CRISPR Build on Casgevy's Success With Its In Vivo Pipeline? CRSP aims to extend its gene-editing lead with in vivo candidates after Casgevy's ex vivo breakthrough success. zacks.com - 2 weeks ago
8. Profile Summary

CRISPR Therapeutics AG CRSP

image
COUNTRY CH
INDUSTRY Biotechnology
MARKET CAP $ 3.82 B
Dividend Yield 0.00%
Description CRISPR Therapeutics AG, a gene editing company, focuses on developing gene-based medicines for serious diseases using its proprietary Clustered Regularly Interspaced Short Palindromic Repeats (CRISPR)/CRISPR-associated protein 9 (Cas9) platform. Its CRISPR/Cas9 is a gene editing technology that allows for precise directed changes to genomic DNA. The company has a portfolio of therapeutic programs across a range of disease areas, including hemoglobinopathies, oncology, regenerative medicine, and rare diseases. The company's lead product candidate is CTX001, an ex vivo CRISPR gene-edited therapy for treating patients suffering from transfusion-dependent beta-thalassemia or severe sickle cell disease in which a patient's hematopoietic stem cells are engineered to produce high levels of fetal hemoglobin in red blood cells. It also develops CTX110, a donor-derived gene-edited allogeneic CAR-T investigational therapy targeting cluster of differentiation 19 positive malignancies; CTX120, a donor-derived gene-edited allogeneic CAR-T investigational therapy targeting B-cell maturation antigen for the treatment of relapsed or refractory multiple myeloma; and CTX130, a donor-derived gene-edited allogeneic CAR-T investigational therapy targeting Cluster of Differentiation 70 to treat various solid tumors and hematologic malignancies. In addition, the company develops VCTX210, a gene-edited immune-evasive stem cell-derived product candidate for the treatment of treatment of type 1 diabetes; and pursues various in vivo gene-editing programs that target the liver, lung, muscle, and central nervous system diseases. It has strategic partnerships with Bayer Healthcare LLC, Vertex Pharmaceuticals Incorporated, ViaCyte, Inc., Nkarta, Inc., and Capsida Biotherapeutics. CRISPR Therapeutics AG was incorporated in 2013 and is headquartered in Zug, Switzerland.
Contact Baarerstrasse 14, Zug, 6300 https://www.crisprtx.com
IPO Date Oct. 19, 2016
Employees 393
Officers Dr. Daniel G. Anderson Ph.D. Scientific Founder & Advisory Board Member Dr. Matthew Porteus M.D., Ph.D. Scientific Founder & Advisory Board Member Dr. Craig C. Mello Ph.D. Scientific Founder & Advisory Board Member Dr. Raju Yashaswi Prasad Ph.D. Chief Financial Officer Dr. Samarth Kulkarni Ph.D. Chief Executive Officer & Chairman Mr. James R. Kasinger J.D. General Counsel & Secretary Dr. Naimish Patel C.M., M.D. Chief Medical Officer Mr. Shaun Foy CFA Founder Dr. Emmanuelle Marie Charpentier Ph.D. Co-Founder & Scientific Advisory Board Member Dr. Chad A. Cowan Ph.D. Scientific Founder